Latest From Biotech Now

Answering the Call for Cures in Michigan

21st Century Cures Act

This week, the Kalamazoo Gazette published an op-ed on how we can accelerate the discovery, development and delivery of treatments and cures for patients written by Stephen Rapundalo, President and CEO of MichBio, and BIO’s Jim Greenwood. The op-ed highlights the focus of roundtable discussions being held across the country as part of the 21st Century Cures Initiative. The U.S. House of Representatives’ Energy and Commerce Committee launched the initiative – led by Chairman Fred Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

USDA Illuminates the Economic Benefits of Moving Toward a Biobased Economy

USDA biopreferred

“A bioeconomy is one based on the use of research and innovation in the biological sciences to create economic activity and public benefit.” - White House (2012) The U.S. Department of Agriculture (USDA)  Secretary Tom Vilsack has recently announced the release of a comprehensive report synthesizing current literature that explores opportunities in the emerging bioeconomy.  The report, entitled Why Biobased?, was created by the USDA as a precursor for a more comprehensive economic study to be released in the coming months by the USDA BioPreferred Read More >

Environmental & Industrial  |  Leave a comment  |  Email This Post
Tags: , , , , ,

2014 BIO Investor Forum Fireside Chat with Nick Leschly and Chris Collins

bluebird bio

Nick Leschly has served as bluebird bio’s president and chief executive officer since September 2010. Previously, he served as interim chief executive officer from March 2010 to September 2010. Formerly a partner of Third Rock Ventures, L.P. since its founding in 2007, Mr. Leschly played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Blurred Lines: Investors Explain Their Re-Thinking of Traditional Private-Only or Public-Only Investment Strategies

DSC_8551

The recent expansion and acceleration of the biotech stock market has seen a new willingness and in some cases eagerness to pursue crossover investing in firms pre- and post-IPO. Venture capitalists have become less dogmatic about funding stage and equity share when positive returns seem nearly guaranteed and investment banks are engaging in discussions with entrepreneurs earlier than ever. Relatedly, corporate venture capital executives’ missions have broadened to consider more diverse forms of collaboration than Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Electroceuticals and Digital Drug Delivery: Neurological Stimulation and Beyond

electroceuticals panel

Some of the most experienced executives in biotechnology have begun asking themselves, “Can we foresee the day of diminishing returns from research in traditional molecular biology?” These researchers are investigating alternative modalities of providing therapy that would combine electronic sensing with drug delivery or even stimulating the body through electricity alone to produce a desired response. These “electroceutical,” or “bioelectronics,” approaches have produced exciting results in early clinical trials, particularly related to insulin control and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,